SS-31 (Elamipretide): Mitochondria-Targeting Peptide

Mitochondrial dysfunction underlies nearly every chronic disease of aging — from heart failure and Alzheimer's to sarcopenia and metabolic syndrome. SS-31, also known as elamipretide or MTP-131, is a synthetic tetrapeptide specifically engineered to penetrate mitochondrial membranes and restore bioenergetic function. Unlike general antioxidants, SS-31 acts at the site where oxidative damage originates.

What Is SS-31 and How Does It Work?

SS-31 is a cell-permeable peptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. Its alternating aromatic and cationic amino acids allow it to selectively accumulate in the inner mitochondrial membrane, reaching concentrations up to 5,000-fold higher than the cytoplasm.

Once there, SS-31 binds cardiolipin — a phospholipid unique to the inner mitochondrial membrane that is essential for organizing the electron transport chain complexes. During oxidative stress and aging, cardiolipin oxidizes and loses its structural integrity, causing cytochrome c to detach and electron transport to become uncoupled. SS-31 stabilizes cardiolipin, keeps cytochrome c functional, and preserves ATP synthase activity.

The result is improved mitochondrial respiration, reduced reactive oxygen species (ROS) production, and protection against the permeability transition pore opening that triggers cell death.

Clinical Research and Applications

SS-31 has advanced further in clinical trials than most research peptides. Stealth BioTherapeutics conducted multiple Phase II trials under the name elamipretide:

Heart failure: The MMAD trial demonstrated that SS-31 infusion improved cardiac energetics measurable by phosphocreatine-to-ATP ratios in patients with heart failure and preserved ejection fraction (HFpEF). Patients reported improved exercise tolerance.

Barth syndrome: This rare genetic mitochondrial disease causes severe cardiomyopathy. A Phase II trial showed elamipretide improved cardiac function, exercise capacity, and quality of life in Barth syndrome patients.

Primary mitochondrial myopathy: The MMPOWER-3 trial, while not meeting its primary endpoint statistically, showed meaningful improvements in patient-reported function for a subset of patients.

Aging research: Animal studies show SS-31 reverses age-related declines in cardiac function, skeletal muscle performance, and kidney health in aged rodents — even when initiated late in life.

Dosing and Administration

In clinical trials, elamipretide has been administered as subcutaneous injections at doses ranging from 4 mg to 40 mg per day. Most research protocols use 4-10 mg subcutaneous once daily.

The peptide has a short half-life of approximately 2-3 hours, which is why daily injection is preferred over less frequent dosing. Intravenous infusion has been used in acute cardiac settings.

Topical formulations are in development for ocular and dermatologic applications, given SS-31's ability to penetrate cell membranes without a delivery system.

Safety Profile

In clinical trials, SS-31/elamipretide has been well tolerated. The most common adverse effects are injection site reactions — redness, bruising, and mild pain. Systemic adverse events have been similar to placebo in most trials.

No significant renal, hepatic, or cardiac toxicity has been observed in human studies. Long-term safety beyond 12 months has not been formally established in large controlled trials.

Regulatory Status

Elamipretide does not hold FDA approval for any indication as of early 2026. Stealth BioTherapeutics filed for FDA approval for Barth syndrome but the application faced significant regulatory hurdles. The compound remains an investigational drug and is not available through commercial pharmacies.

Researchers and clinicians investigating mitochondrial medicine may access it through compassionate use or clinical trial enrollment.

FAQ

How is SS-31 different from CoQ10 or MitoQ? CoQ10 and MitoQ are antioxidants that accept electrons in the mitochondrial chain but do not specifically stabilize cardiolipin. SS-31 acts earlier in the dysfunction cascade by preserving membrane architecture, which is a more fundamental intervention.

Can SS-31 reverse mitochondrial aging? In animal models, yes — it restores function comparable to young animals when given to aged mice. Human data are limited but show bioenergetic improvements. Whether functional reversal translates to longevity extension in humans is unknown.

Where can I obtain SS-31? Currently only through clinical trials or compassionate use programs. It is not available as a research peptide from compounding pharmacies, unlike BPC-157 or TB-500.

Related Articles

• Peptides for Cardiovascular Health: SS-31, Cortagen, and More
• Peptides for Longevity: Epithalon, SS-31, Humanin, and the Science
• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?

Track your supplements in Optimize.